Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming (PHAR) Other Non-Current Assets (2019 - 2025)

Historic Other Non-Current Assets for Pharming (PHAR) over the last 7 years, with Q3 2025 value amounting to $2.0 million.

  • Pharming's Other Non-Current Assets rose 3016.8% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 3016.8%. This contributed to the annual value of $1.5 million for FY2024, which is 150.52% down from last year.
  • Latest data reveals that Pharming reported Other Non-Current Assets of $2.0 million as of Q3 2025, which was up 3016.8% from $2.7 million recorded in Q2 2025.
  • Over the past 5 years, Pharming's Other Non-Current Assets peaked at $2.7 million during Q2 2025, and registered a low of -$20000.0 during Q1 2022.
  • Moreover, its 5-year median value for Other Non-Current Assets was $1.3 million (2022), whereas its average is $1.1 million.
  • As far as peak fluctuations go, Pharming's Other Non-Current Assets crashed by 10207.9% in 2022, and later skyrocketed by 616000.0% in 2023.
  • Over the past 5 years, Pharming's Other Non-Current Assets (Quarter) stood at $450724.6 in 2021, then surged by 191.09% to $1.3 million in 2022, then rose by 16.46% to $1.5 million in 2023, then fell by 1.51% to $1.5 million in 2024, then skyrocketed by 33.89% to $2.0 million in 2025.
  • Its Other Non-Current Assets was $2.0 million in Q3 2025, compared to $2.7 million in Q2 2025 and $1.6 million in Q1 2025.